Cleveland BioLabs (CBLI) Earning Somewhat Positive Media Coverage, Analysis Shows
News articles about Cleveland BioLabs (NASDAQ:CBLI) have trended somewhat positive on Saturday, Accern Sentiment Analysis reports. The research firm rates the sentiment of news coverage by monitoring more than 20 million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Cleveland BioLabs earned a coverage optimism score of 0.18 on Accern’s scale. Accern also assigned news stories about the biotechnology company an impact score of 44.3016093085546 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the next few days.
Shares of Cleveland BioLabs (NASDAQ:CBLI) opened at $4.01 on Friday. The firm has a market capitalization of $45.23, a price-to-earnings ratio of -4.56 and a beta of -0.32. Cleveland BioLabs has a fifty-two week low of $1.35 and a fifty-two week high of $5.55.
Cleveland BioLabs (NASDAQ:CBLI) last posted its quarterly earnings data on Tuesday, November 14th. The biotechnology company reported ($0.11) earnings per share for the quarter. The firm had revenue of $0.30 million during the quarter. Cleveland BioLabs had a negative net margin of 472.44% and a negative return on equity of 91.87%.
TRADEMARK VIOLATION WARNING: “Cleveland BioLabs (CBLI) Earning Somewhat Positive Media Coverage, Analysis Shows” was originally posted by TheOlympiaReport and is owned by of TheOlympiaReport. If you are accessing this article on another publication, it was copied illegally and republished in violation of United States & international trademark & copyright laws. The legal version of this article can be read at https://theolympiareport.com/2017/12/30/cleveland-biolabs-cbli-earning-somewhat-positive-media-coverage-analysis-shows.html.
About Cleveland BioLabs
Cleveland BioLabs, Inc (CBLI) is a biopharmaceutical company. The Company is engaged in developing approaches to activate the immune system and address serious medical needs. Its platform of Toll-like immune receptor activators has applications in mitigation of radiation injury and immuno-oncology. Its advanced product candidate is Entolimod, an immuno-stimulatory agent, which it is developing as a radiation countermeasure and an immunotherapy for oncology and other indications.
Receive News & Ratings for Cleveland BioLabs Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cleveland BioLabs and related companies with MarketBeat.com's FREE daily email newsletter.